Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide combined with induction chemotherapy for stage 4/M neuroblastoma
ChiCTR1800014748Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in neuroblastoma, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective response rate after ATO-combined induction chemotherapy. Started Jan 2019; status: recruiting.
02
Drugs
arsenic trioxide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on ChiCTR1800014748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014748.